They are used against tyrosine kinase receptors or their ligands, mainly VEGF, to block angiogenesis [82], or more recently targeting immune checkpoint molecules especially in anaplastic thyroid cancer models [83]. This evidence concerns the gene VEGFA and thyroid gland undifferentiated (anaplastic) carcinoma.